Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (Q3)Dec 31, 2025 | (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 125.35%290.92K | 62.80%-396.73K | 61.85%-454.91K | -12.87%-5.55M | 7.03%-2.14M | -216.98%-1.15M | -8.53%-1.07M | 54.32%-1.19M | -35.03%-4.92M | -55.84%-2.3M |
| Net income from continuing operations | 447.69%10.47M | -102.39%-70.2K | -979.33%-11.63M | 99.96%-30.25K | 98.09%-1.28M | -936.64%-3.01M | 701.20%2.94M | 159.18%1.32M | -1,041.76%-69.45M | -2,324.24%-67.08M |
| Operating gains losses | -260.54%-10.52M | --0 | 568.35%10.83M | -176.06%-5.39M | -171.54%-5.18M | 5,877.49%6.55M | -76,290.76%-4.44M | -4,204.15%-2.31M | 7,354.32%7.08M | 1,402.09%7.25M |
| Depreciation and amortization | -72.43%635 | -68.55%636 | -27.28%1.23K | -91.36%8.46K | -91.52%2.45K | -89.81%2.3K | -91.35%2.02K | -92.69%1.69K | 6.13%97.93K | 11.11%28.88K |
| Asset impairment expenditure | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | -115.26%-8.1K | -200.26%-53.22K |
| Unrealized gains and losses of investment securities | --0 | --0 | --219.44K | ---- | ---- | ---4.62M | --0 | --0 | ---- | ---- |
| Remuneration paid in stock | -353.84%-104.25K | 142.42%90.83K | -62.89%90.83K | -83.28%94.68K | -93.03%22.95K | -83.44%41.07K | 0.42%-214.12K | 19.99%244.78K | 26.00%566.28K | 167.39%329.3K |
| Other non cashItems | ---83.65K | --0 | --83.62K | -99.39%349.88K | -98.48%870.14K | ---- | ---- | ---- | 46,412.71%57.28M | 75,417.18%57.21M |
| Change In working capital | 26.71%523.03K | -164.21%-418K | 90.30%-43.65K | -20.01%-584.29K | -8,932.87%-1.2M | -7.22%412.78K | 288.70%650.95K | 25.05%-450.02K | -126.74%-486.87K | -99.13%13.56K |
| -Change in receivables | 10.08%351.14K | -4,927.07%-341.09K | -50.26%32.43K | 355.00%36.49K | -322.02%-340.93K | 361.49%318.99K | -104.66%-6.79K | -0.19%65.21K | 111.85%8.02K | -2.88%-80.79K |
| -Change in prepaid assets | -102.51%-3.66K | --0 | -62.39%48.18K | -67.18%80.29K | 30.67%-293.74K | -75.16%145.63K | 2,138.41%100.29K | 47.10%128.11K | 143.39%244.65K | 33.30%-423.68K |
| -Change in payables and accrued expense | 438.64%175.55K | -113.80%-76.91K | 80.68%-124.26K | 5.20%-701.06K | -208.75%-563.34K | -169.41%-51.84K | 214.82%557.45K | 14.54%-643.34K | -130.16%-739.53K | -77.28%518.02K |
| -Change in other current assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---17.72K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 125.35%290.89K | 62.80%-396.73K | 61.85%-454.91K | -12.87%-5.55M | 7.03%-2.14M | -216.98%-1.15M | -8.53%-1.07M | 54.32%-1.19M | -35.03%-4.92M | -55.84%-2.3M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -39,294.18%-6.54M | 0 | -226,730.18%-8.11M | 98.45%-15.32K | 98.31%-97 | 98.16%-16.59K | 97.21%-2.21K | 490.19%3.58K | -130.15%-990.07K | -100.63%-5.75K |
| Net PPE purchase and sale | --0 | --0 | --0 | 98.61%-13.74K | -103.27%-143 | 99.47%-4.82K | 96.63%-2.77K | -556.05%-6.02K | -274.13%-988.05K | -99.52%4.37K |
| Net business purchase and sale | ---6.54M | --0 | ---7.76M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net investment purchase and sale | ---- | --0 | ---345.3K | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Net other investing changes | ---- | ---- | ---- | 21.91%-1.58K | 100.45%46 | -323.84%-11.78K | --557 | --9.59K | 98.78%-2.02K | -355.74%-10.12K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -1,789.66%-313.57K | --0 | -226,730.18%-8.11M | 98.45%-15.32K | 98.31%-97 | 98.16%-16.59K | 97.21%-2.21K | 490.19%3.58K | -130.15%-990.07K | -100.63%-5.75K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | -96.24%121K | -30.02%479K | 192.33%13.39M | -85.03%472.3K | 1,353.49%9.02M | 160.82%3.21M | -25.08%684.5K | 54.79%4.58M | 190.29%3.16M |
| Net issuance payments of debt | --0 | --0 | --0 | -57.52%1.44M | -97.96%69.9K | --0 | -28.37%683.2K | 91,123.94%684.5K | 106,263.33%3.38M | 226,014.22%3.43M |
| Net common stock issuance | --0 | --121K | --479K | ---- | ---- | --0 | --0 | --0 | -60.05%1.2M | -124.55%-275.65K |
| Net other financing activities | ---- | ---- | ---- | 898.50%11.96M | --402.4K | --9.02M | ---- | ---- | 3,591.05%1.2M | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | -96.24%121K | -30.02%479K | 192.33%13.39M | -85.03%472.3K | 1,353.49%9.02M | 160.82%3.21M | -25.08%684.5K | 54.79%4.58M | 190.29%3.16M |
| Net cash flow | ||||||||||
| Beginning cash position | -80.44%528.11K | 44.95%803.84K | 739.53%8.89M | -55.58%1.06M | 4,846.97%10.56M | 215.21%2.7M | -19.18%554.54K | -55.58%1.06M | -31.80%2.38M | -88.57%213.45K |
| Current changes in cash | -100.29%-22.68K | -112.85%-275.73K | -1,503.45%-8.08M | 691.11%7.83M | -297.66%-1.67M | 1,322.25%7.86M | 1,159.47%2.15M | 70.29%-504.21K | -19.20%-1.32M | 63.79%845.3K |
| End cash Position | -95.21%505.42K | -80.44%528.11K | 44.95%803.84K | 739.53%8.89M | 739.53%8.89M | 4,846.97%10.56M | 215.21%2.7M | -19.18%554.54K | -55.58%1.06M | -55.58%1.06M |
| Free cash from | 125.24%290.89K | 62.89%-396.73K | 62.04%-454.91K | 5.79%-5.56M | 6.84%-2.14M | -1,709.86%-1.15M | -0.42%-1.07M | 54.10%-1.2M | -51.20%-5.9M | -300.07%-2.3M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.